Format

Send to

Choose Destination
Br J Pharmacol. 2016 Jun;173(11):1728-41. doi: 10.1111/bph.13464. Epub 2016 Apr 21.

New use for an old drug: COX-independent anti-inflammatory effects of sulindac in models of cystic fibrosis.

Author information

1
Inserm, U955, Equipe 5, Créteil, France.
2
Université Paris Est, UPEC, Créteil, France.
3
DHU Ageing-Thorax-Vessel-Blood, Créteil, France.
4
AP-HP, Hôpital H. Mondor-A. Chenevier, Pôle de Biologie, Créteil, France.
5
CHIC, service d'ORL, Créteil, France.
6
McGill University, Montréal, Canada.

Abstract

BACKGROUND AND PURPOSE:

Pulmonary disease is the main cause of morbidity and mortality in cystic fibrosis (CF) patients due to exacerbated inflammation. To date, the only anti-inflammatory drug available to CF patients is high-dose ibuprofen, which can slow pulmonary disease progression, but whose cyclooxygenase-dependent digestive adverse effects limit its clinical use. Here we have tested sulindac, another non-steroidal anti-inflammatory drug with an undefined anti-inflammatory effect in CF airway epithelial cells.

EXPERIMENTAL APPROACH:

Using in vitro and in vivo models, we NF-κB activity and IL-8 secretion. In HeLa-F508del cells, we performed luciferase reporter gene assays in order to measure i) IL-8 promoter activity, and ii) the activity of synthetic promoter containing NF-κB responsive elements. We quantified IL-8 secretion in airway epithelial CFBE cells cultured at an air-liquid interface and in a mouse model of CF.

KEY RESULTS:

Sulindac inhibited the transcriptional activity of NF-κB and decreased IL-8 transcription and secretion in TNF-α stimulated CF cells via a cyclooxygenase-independent mechanism. This effect was confirmed in vivo in a mouse model of CF induced by intra-tracheal instillation of LPS, with a significant decrease of the induction of mRNA for MIP-2, following treatment with sulindac.

CONCLUSION AND IMPLICATIONS:

Overall, sulindac decrease lung inflammation by a mechanism independent of cycolooxygenase. This drug could be beneficially employed in CF.

PMID:
26894321
PMCID:
PMC4867744
DOI:
10.1111/bph.13464
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center